Key facts
- This page summarizes Neil E. Stahl's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Dec 2024, 16:02.
Neil E. Stahl - 16 Dec 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)
- Reporting relationship
- EVP Research and Development
- Issuer ticker
- REGN
- Reported as of
- 16 Dec 2024
- Net transaction value
- -$222,166
- SEC form
- 4
- Accepted by SEC
- 18 Dec 2024, 16:02:59 UTC
- Prior SEC filing
- 10 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Neil E. Stahl
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Neil E. Stahl filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 18 Dec 2024.
Change
- Previous filing in this sequence was filed on 10 Dec 2024.
- Current net transaction value: -$222,166.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $222,166
- Shares
- -304
- Change %
- -0.62%
- Price
- $730.81
- Shares after
- 48,829
- Date
- 16 Dec 2024
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,849
- Date
- 16 Dec 2024
- Ownership
- By 401(k) Plan
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,605
- Date
- 16 Dec 2024
- Ownership
- by Spouse as Trustee
* marks a reported price that did not pass the local price check.